Pharmacological treatments for ADHD

Progress in Neurology and Psychiatry

Volumn 13, Issue 4, 2009, Pages 17-26

  Parker, Caroline ^a  

^a CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CLONIDINE; DEXAMPHETAMINE; IMIPRAMINE; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; BLURRED VISION; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; GROWTH DISORDER; HEART PALPITATION; HUMAN; INDIGESTION; INSOMNIA; MORNING DOSAGE; MOTOR DYSFUNCTION; NAUSEA AND VOMITING; NERVOUSNESS; ORTHOSTATIC HYPOTENSION; PRESCRIPTION; PRIORITY JOURNAL; PRURITUS; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT DURATION; TREATMENT PLANNING; WEIGHT REDUCTION;

EID: 70350294655     PISSN: 13677543     EISSN: None     Source Type: Journal    
DOI: 10.1002/pnp.128     Document Type: Review

References (36)

1. Nutt DJ, Fone K, Asherson P, et al. Evidence based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 2006.
2. National Institute for Health and Clinical Excellence, 2008. Clinical Guideline 72. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. http://www.nice.org.uk.
3. National Institute for Health and Clinical Excellence, 2006. Technology Appraisal 98. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13. http://www.nice.org.uk/ nicemedia/pdf/TA098guidance.pdf
4. European Clinical Guidelines for hyperkinetic disorder - first upgrade. Taylor E et al. Eur Child Adolesc. Psychiatry 2004;13(Suppl 1):17-30.
5. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomised open-label trial. J Am Acad Child Adolesc Psychiatry 2002;41(7):776-84.
6. Swanson JM, Kraemer HC, Hinshaw SP. Clinical relevance of the primary findings of the MTA: success rates based on severity of symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 2001; 40:168-79.
7. MTA Cooperative Group 14-month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-86.
8. Jensen P, Arnold LE, Swanson JM, et al. 3-Year Follow-up of the NIMH MTA Study. J Am Acad Child Adolesc Psychiatry 2007;46(8):989-1002.
9. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder. Arch Gen Psychiatry 2003;60:204-11.
10. Pelham W, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 2001;107(6):1-15.
11. Wolraich M, Greenhill LL, Pelham W, et al. Randomised, controlled trial of OROS methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics 2001;108(4): 883-92.
12. Dexedrine (dexamfetamine) Summary of Product Characteristics last updated on the eMC: 24/09/2008. UCB Pharma Limited. Electronic Medicines Compendium: http://emc.medicines.org.uk/
13. Michelson D, Allen AJ, Busner J, et al. Once-daily Atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomised, placebo controlled study. Am J Psychiatry 2002;159:1896-901.
14. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention deficit/ hyperactivity disorder: a randomised, placebo-controlled, dose-response study. Pediatrics 2001;108(5)e83:1-9.
15. Spencer T, Heiligenstein JH, Beiderman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63(12):1140-7.
16. Kratochvil CJ, Bohac D, Harrington M, et al. An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001;11(2):167-70.
17. Spencer D, Beiderman J, Heiligenstein J, et al. An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adoles Psychopharmacol 2001;11(3):251-65.
18. Heil SH, Holmes HW, Bickel WK, et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug and Alcohol Dependence 2002;67:149-56.
19. Ritalin (Methylphenidate) Summary of Product Characteristics last updated on the eMC: 20/01/2009. Novartis Pharmaceuticals UK Ltd. Electronic Medicines Compendium: http://emc.medicines.org.uk/
20. Straterra (Atomoxetine) Summary of Product Characteristics last updated on the eMC: 22/11/2008. Eli Lilly and Company Limited. Electronic Medicines Compendium: http://emc.medicines.org.uk/
21. Concerta (Methylphenidate) Summary of Product Characteristics last updated on the eMC: 04/08/2008. Janssen-Cilag Ltd. Electronic Medicines Compendium: http://emc.medicines.org.uk/
22. Wernicke JF, Kratochivil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002;63(Suppl 12):50-5.
23. Biederman J, Wilens T, Mick E, et al. Pharmacotherapy of Attention-deficit/Hyperactivity Disorder Reduces Risk for Substance Use Disorder. Pediatrics 1999;104(2):e20.
24. CSM Dear Colleague letter, Professor G Duff, Chairman, Committee on Safety of Medicines. 2 February 2005 CEM/CMO/2005/) Strattera (Atomoxetine) - Risk Of Hepatic Disorders.
25. MHRA 29. September 2005, Questions and Answers. Suicidal thoughts in children and adolescents treated with Strattera (atomoxetine).
26. Equasym XL (Methylphenidate) Summary of Product Characteristics last updated on the eMC: 21/09/2006. UCB Pharma Limited. Electronic Medicines Compendium: http://emc.medicines.org.uk/
27. Medikinet XL (Methylphenidate) Summary of Product Characteristics last updated on the eMC: 26/02/2007 Flynn Pharma Ltd. Electronic Medicines Compendium: http://emc.medicines.org.uk/
28. British National Formulary for Children. 2008. London: BMJ Publishing Group, RPS Publishing and RCPCH Publications; 2008. http://bnfc.org/bnfc/ bnfc/2008/200535.htm
29. Spencer T, Beiderman J, Wilens T. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693-5.
30. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-20.
31. Adler LA, Spencer TJ, Williams DW, et al. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study. J Attention Dis 2008;12(3):248-53.
32. British National Formulary. 56th Edition. London: BMJ Publishing Group Ltd and RPS Publishing; September 2008. http://www.bnf.org/bnf/
33. New Drugs Online. UK Medicines Information www.ukmi.nhs.uk
34. Biederman J. Introduction: New Developments in the Treatment of Attention-Deficit/Hyperactivity Disorder. J Clin Psychiatry 2006; 67(Suppl 8):4-6.
35. National Service Framework for Children, Young People and Maternity Services: The mental health and psychological wellbeing of children and young people. Department of Health; Department for Education and Skills. 15 September 2004. http://www.dh.gov.uk/en/Healthcare/ NationalServiceFrameworks/Children/DH_4089111
36. National Service Framework for Children, Young People and Maternity Services: Medicines for Children and Young People. Department of Health; Department for Education and Skills. 15 September 2004. http://www.dh.gov.uk/en/Healthcare/NationalServiceFrameworks/Children/ DH_4089111